AstraZeneca: diabetes drug meets clinical trial endpoint
(CercleFinance.com) - A late-stage trial of AstraZeneca's Farxiga found that it reduced the need for hospitalisation for heart failure or cardiovascular death in patients with type-2 diabetes, the company said Monday.
The Phase III trial evaluating Farxiga compared to placebo over a period of up to five years across 33 countries and in over 17,000 adults met its primary safety endpoint of non-inferiority for major adverse cardiovascular events, it said.
Farxiga achieved a statistically-significant reduction in the composite endpoint of hospitalisation for heart failure or cardiovascular death, one of the two primary efficacy endpoints.
In addition, fewer major adverse cardiovascular events were observed with Farxiga for the other primary efficacy endpoint, however, this did not reach statistical significance.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The Phase III trial evaluating Farxiga compared to placebo over a period of up to five years across 33 countries and in over 17,000 adults met its primary safety endpoint of non-inferiority for major adverse cardiovascular events, it said.
Farxiga achieved a statistically-significant reduction in the composite endpoint of hospitalisation for heart failure or cardiovascular death, one of the two primary efficacy endpoints.
In addition, fewer major adverse cardiovascular events were observed with Farxiga for the other primary efficacy endpoint, however, this did not reach statistical significance.
Copyright (c) 2018 CercleFinance.com. All rights reserved.